New drug combo for advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug, HRS-4508, given with other cancer treatments for people with advanced non-small cell lung cancer whose previous treatments have failed. The goal is to see if this combination can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your lung cancer is advanced or has spread, and standard treatments have stopped working or cause too many side effects.
- You are able to take care of yourself and get around (ECOG score 0 or 1).
- You have at least one tumor outside the brain that can be measured on scans.
- You do not have untreated or actively growing brain tumors.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination for people with advanced non-small cell lung cancer (NSCLC) that has a specific gene change (EGFR mutation or MET-positive) and has worsened after prior treatment. It aims to see if the combination is safe and effective.
This early-stage trial tests a new drug combination (HS-20122) for non-small cell lung cancer that has spread or cannot be surgically removed. You may qualify if your cancer has progressed despite prior treatment or you haven't received prior treatment yet.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial tests an experimental drug called HRS-4508 for people with advanced non-small cell lung cancer that has stopped responding to standard treatments or cannot tolerate them. The goal is to see if it can shrink tumors or slow cancer growth.
This trial tests a combination of a targeted chemotherapy bead injection into lung arteries, an oral anti-cancer drug, and an immunotherapy for advanced non-small cell lung cancer that has not responded to two prior treatments. It aims to see if this triple approach can help patients who have limited options left.
This trial tests a new drug, HRS-4642, combined with other cancer treatments for people with advanced solid tumors. It looks at how well the combination works and if it is safe for you.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.